Can engineered viruses help fight superbugs? A new review maps a path forward

Imagine an infection that doesn't respond to any antibiotic. That's the terrifying reality of drug-resistant superbugs. Scientists are looking for new weapons, and one promising idea is using engineered viruses—called bacteriophages—that naturally hunt and kill specific bacteria. A new review explains how researchers are now designing these phages with tools like CRISPR to make them more precise and pairing them with imaging techniques to see where infections are hiding in the body. The review focuses on major drug-resistant threats, including Pseudomonas, MRSA, and tuberculosis-like bacteria. The goal is to create a measurable, adaptable treatment framework. But the authors are clear: this is a proposed roadmap, not a finished product. Significant practical hurdles stand in the way, including how to manufacture these therapies consistently, how to keep the body's immune system from neutralizing them, and navigating varying regulatory requirements. The proposed development pathway starts in animal models and would need to progress through carefully defined clinical trials. This review helps organize the conversation about a promising but complex future for fighting superbugs.